Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
about
Mycophenolate mofetil (MMF) for the treatment of connective tissue disease-associated interstitial lung disease (ILD)My approach to the treatment of sclerodermaManagement of Systemic-Sclerosis-Associated Interstitial Lung DiseaseUpdate on biomarkers in systemic sclerosis: tools for diagnosis and treatmentRenal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and managementRaynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and managementRecommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertensionSystemic sclerosis with thrombotic thrombocytopenia purpura and malignant hypertension.Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience.Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patientsDiagnosis and management of pulmonary hypertension in systemic sclerosis.Scleroderma lung diseaseInterstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.Echocardiography may help detect pulmonary vasculopathy in the early stages of pulmonary artery hypertension associated with systemic sclerosis.Registry evaluation of digital ulcers in systemic sclerosis.Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry.Cardiac manifestations in systemic sclerosis.Comparing HLA shared epitopes in French Caucasian patients with scleroderma.Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings.Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Clinical and autoimmune profile of scleroderma patients from Western India.Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?Renal involvement in autoimmune connective tissue diseases.Ocular findings in patients with systemic sclerosis.Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.Late-age onset systemic sclerosis.Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patientsMissing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient!Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical featuresEffect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysisSubspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group.Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus.Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular diseaseIncidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients.A prediction model for progressive disease in systemic sclerosisImpaired skeletal muscle microcirculation in systemic sclerosis.
P2860
Q24203019-3DE80AE4-7208-4484-AD92-76E97586A2A6Q24618843-B31D5F1E-E3F7-4C14-B195-523D4886B64BQ26799573-8AE77AE3-59D1-4BEC-8F8F-371B8FEB5EB6Q26995542-D7ADC210-41A7-4592-830C-26D60258BF22Q27023769-E0C868A3-CCBC-480F-931D-D5BC2D5146DFQ28392431-9FAC17D1-D8F5-4FA8-9DFB-C947F5D8CC2CQ30562538-2083795F-98FA-43D1-9B92-BECFFE02557CQ33402720-C46238A5-70BA-4B49-8D3F-0F7915F24048Q33727800-C648382B-143D-4AC8-849F-8F7B5950CFAFQ33737250-B263B32F-4960-4D78-930D-83C628DAC466Q33765684-897B27C1-8DA1-4FF4-ACB9-A302339A106FQ33832379-AC479A83-8F9D-48E5-AF6C-E460EBAAAD79Q33919119-0A61F147-6A90-4DDA-ADD8-F5B644E2D564Q33956830-FF17A78B-FC9C-4020-9576-AD0679938C7EQ34013946-DE23EF50-428F-41AE-8BD5-0B891425BAA4Q34123635-BE76E5BA-20BE-45F9-BC10-C5680A7B723EQ34128276-A8F7CA37-50BF-46EE-81F8-7D5F7B62835AQ34251904-FDD6D47B-2734-4B82-AB48-51D126409679Q34277474-98782914-5413-48E2-805F-82726EE1C812Q34295337-13CF5DC3-CA51-477A-B7A7-78D384B8B654Q34409802-0C5ED642-392E-4A2D-8615-05BAC8A8E213Q34438113-0F56918B-BDDE-4871-B9CC-C9752B1DFAAEQ34448474-7FBDD9F5-026B-49C2-994C-9A92F8DB1706Q34567867-F8F66CAA-CEED-409C-B97C-4369CE2DD8DCQ34654954-E067A56C-F00A-4042-BDB0-4EB118AC0F19Q34768694-BF8EAF05-92B1-453D-B21C-E3C20BF7F692Q35048672-4CDA1506-4D1C-4C11-BBB6-D3B5CD423536Q35106951-82A9C2AE-2124-48FC-9CEF-0E3D9C8E7248Q35223302-8014245E-F26F-485E-8E60-16B3F586A1C7Q35309739-EE9B3ADC-9F7F-478E-B5DA-796AFFECEB40Q35840816-C11AAF1F-5D28-4180-A4A1-DB42B05A36CEQ35977704-9B9F0DC4-776D-4204-8F9A-C9ADE12C8405Q36060142-1552D619-A0D4-4372-875B-53D6456E3CCCQ36085041-A0E99767-B477-4217-9A21-A9EC599C6855Q36129874-0DAA9A55-7556-4336-B397-9FDF8B31AD0DQ36130814-83BCB804-9067-489E-BC1E-C0C2524AB483Q36153763-57CBA28A-C1FE-47FD-87A9-02B449EFF711Q36193496-92A526B8-EB31-4DF1-B919-07DC3122B444Q36375900-B709CA79-7304-477C-AC76-83793A4CBB5AQ36633168-6EACCCE5-773A-485F-9E05-4805C07334E9
P2860
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clinical risk assessment of or ...... ls And Research group database
@ast
Clinical risk assessment of or ...... ls And Research group database
@en
type
label
Clinical risk assessment of or ...... ls And Research group database
@ast
Clinical risk assessment of or ...... ls And Research group database
@en
prefLabel
Clinical risk assessment of or ...... ls And Research group database
@ast
Clinical risk assessment of or ...... ls And Research group database
@en
P2093
P2860
P50
P356
P1476
Clinical risk assessment of or ...... ls And Research group database
@en
P2093
C Bocelli-Tyndall
D Farge-Bancel
U A Walker
P2860
P304
P356
10.1136/ARD.2006.062901
P407
P577
2007-01-18T00:00:00Z